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Short-term effects of anastrozole therapy on serum lipid profile
in patients with breast cancer, previously treated with tamoxifen.
Preliminary report*
Janusz Wojtacki1, Wies∏aw J. Kruszewski2, Krzysztof LeÊniewski-Kmak3,
Monika Âliwiƒska1, Katarzyna Czy˝ewska1, El˝bieta Kruszewska1,
Dominik Rachoƒ4
B a c k g r o u n d.  Estrogens play a crucial part in the regulation of lipid metabolism – they decrease the serum concentrations
of total- and low-density lipoprotein (LDL) cholesterol and elevate the concentrations of high-density lipoprotein (HDL) cho-
lesterol. Endocrine therapy of breast cancer patients is aimed at inhibiting estrogen-dependent proliferation of cancer cells. Ta-
moxifen, an antiestrogen used in breast cancer hormonotherapy, exerts beneficial influence on the lipid profile, arising from
its estrogen-like properties. The value of new-generation aromatase inhibitors used sequentially with the initial adjuvant – ta-
moxifen is currently being investigated in a number of clinical trials. There are concerns, however, that the deprivation of es-
trogens by aromatase inhibitors may reverse the beneficial effects of tamoxifen on the serum lipid profile, and thus increase the
risk of coronary heart disease.
A i m  o f  t h e  s t u d y.  To assess the effects of a short-term therapy with anastrozole, a third generation aromatase inhibitor,
on the basic lipid profile in women with breast cancer, who have progressed on tamoxifen.
M a t e r i a l  a n d  m e t h o d s.  The analysis included 44 postmenopausal patients (median age: 64.5 years, range: 47-75), who
were assigned to receive anastrozole. All the patients were previously treated with tamoxifen in adjuvant therapy (n=31) or for
advanced disease (N=13). Anastrozole 1mg was given orally once a day. Concentrations of basic blood lipids and body mass
index values (weight in kilograms divided by squared height in meters) were measured before anastrozole administration and
after 12-32 weeks (median: 13, average: 16.2) of therapy.
R e s u l t s.  There were no statistically significant differences in lipid parameters during anastrozole treatment, namely, the to-
tal cholesterol (p=0.50), LDL-cholesterol (p=0.51), HDL-cholesterol (p=0.69), triglycerides (p=0.95) and the number of
hypercholesterolemic patients (total cholesterol > 5.7 mmol/l; p=0.85). We did not observe any influence of anastrozole ad-
ministration on the body mass index mean values, either (p=0.94).
C o n c l u s i o n.  Our preliminary results indicate that anastrozole does not compromise lipid metabolism during short-term
treatment. The study will be continued to assess long-term effects of anastrozole on the lipid and lipoprotein profile.
Wp∏yw krótkotrwa∏ej terapii anastrozolem na profil lipidowy chorych na raka piersi,
uprzednio leczonych tamoksyfenem. Doniesienie wst´pne
W p r o w a d z e n i e.  Estrogeny odgrywajà kluczowà rolà w regulacji metabolizmu lipidów – powodujà obni˝enie st´˝eƒ cho-
lesterolu ca∏kowitego i zawartego we frakcji lipoprotein o niskiej g´stoÊci (LDL), podwy˝szajà poziom cholesterolu, nale˝àce-
go do frakcji lipoprotein o wysokiej g´stoÊci (HDL). Celem leczenia hormonalnego chorych na raka piersi jest zniesienie dzia-
∏ania estradiolu na komórki nowotworowe. Tamoksyfen, antyestrogen stosowany w hormonoterapii raka piersi, wp∏ywa ko-
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Introduction
Estrogens play an important part in the regulation of lipid
metabolism – they decrease the serum concentration of
total- and low-density lipoprotein (LDL) cholesterol and
elevate the concentration of high-density lipoprotein
(HDL) cholesterol [1-3]. Hormonal treatment of breast
cancer is aimed at eliminating the influence of estrogenes
on neoplastic cells [4]. Tamoxifen, the most frequently
applied drug in breast cancer hormonotherapy, is a non-
-steroidal antiestrogen which blocks intracellular estrogen
receptors (ER) [4]. The drug is, however, known not to be
a simple antiestrogen; apart from an antiestrogenic ef-
fect it is also an ER agonist in postmenopausal women. It
has been found to decrease the loss of bone tissue and
prevent osteoporosis [7, 8]. In adjuvant treatment of bre-
ast cancer cases with tamoxifen there is a decrease in the
total concetrations of cholesterol (by 10-20% on avarage)
and LDL-cholesterol (by some 15-20%), whereas the le-
vel of HDL-cholesterol either increases, or remains un-
changed [4, 6, 9]. Clinically this involves a significant re-
duction in the incidence and mortality from ischaemic
heart disease [10]. The same agonist properties, that pro-
vide the beneficial effect of tamoxifen, to a certain extent
limit its clinical value. The drug and its derivates stimula-
te the proliferation of the endometrium [11] and are asso-
ciated with an increased risk of endometrial cancer [11,
12]. Moreover, some authors suggest that late failure of
adjuvant tamoxifen therapy or de novo resistance to the
drug may be related to its estrogen-like activity [4, 13-
-16]. These observations form a theoretical basis of the
studies aimed at discovering the merits of sequential ad-
juvant treatment of breast cancer cases, where, after the
previous use of tamoxifen, aromatase inhibitors are inten-
tionally administered. Scheduled application of aromata-
se inhibitors in sequence to tamoxifen is expected to redu-
ce a probability of side effects caused by its estrogen-like
properties [16]. There are some concerns, however, that
decreasing estrogene concentration to an indetermina-
ble level may suppress the beneficial effects tamoxifen
has on lipid metabolism and, consequently, increase the
risk of hypoestrogenic-related diseases, including myocar-
dial ischaemia. The current study is aimed at determi-
ning the effect of short-term anastrozole therapy on the li-
pid profile in patients previously on tamoxifen.
Material and methods
Our serial analysis of blood lipid parameters was performed
on 44 postmenopausal breast cancer women aged between 47
and 75 years, (median: 64.5), who, due to progressing neoplastic
disease, were assigned to receive anastrozole therapy. All the
patients had previously received tamoxifen as either adjuvant
therapy (31 cases) or as palliative therapy in advanced disease
(a total of 13 cases: dissemination to the supraclavicular no-
des – 5 patients, to the bones – 6, to the bones and hypodermis
– 1, to the ovary – 1). Following tamoxifen treatment of 3 to 51
months (median: 15) progression of the neoplastic disease was
diagnosed (in 11 cases – local recurrence, in 33 – metastatic
disease: in 21 – bones, in 3 – lungs, in 9 – ipsilateral supraclavi-
cular lymph nodes) and the patients were switched on anastro-
zole. Anastrozole 1 mg was given orally once a day to all the pa-
tients. Median time from tamoxifen discontinuation to the begi-
ning of anastrozole therapy was 10 days (range: 2-14; the
half-life of tamoxifen is 7 days; its biological effects are mainta-
ined approx. 14 days, the half-life of anastrozole is 30 to 60 ho-
urs) [13, 16]. In cases of skeletal metastases irradiation was ap-
plied to the involved areas. All the cases with local recurrence
were initially operated on while radical radiation therapy to
the chest wall and to the regional lymph nodes area was ap-
plied later. In case of metastases to the supraclavicular lymph
nodes palliative radiotherapy was applied to the cervical-su-
praclavicular areas involved. Table I presents the characteri-
stics of the evaluated population.
rzystnie na profil lipidowy dzi´ki w∏aÊciwoÊciom estrogenopodobnym. W aktualnie prowadzonych badaniach klinicznych oce-
nia si´ wartoÊç sekwencyjnej hormonoterapii uzupe∏niajàcej, gdzie po leczeniu tamoksyfenem planowo stosuje si´ leki hamu-
jàce syntez´ estrogenów z grupy inhibitorów aromatazy. Istnieje obawa, ˝e obni˝enie st´˝eƒ krà˝àcych estrogenów mo˝e spo-
wodowaç zniesienie korzystnego wp∏ywu tamoksyfenu na metabolizm lipidów i ryzyko wystàpienia choroby niedokrwiennej ser-
ca.
C e l  p r a c y.  Ocena wp∏ywu krótkotrwa∏ego leczenia anastrozolem, inhibitorem aromatazy trzeciej generacji, na podstawo-
wy profil lipidowy kobiet chorych na raka piersi, u których dotychczas podawano tamoksyfen.
M a t e r i a ∏  i m e t o d y.  Ocenà obj´to grup´ 44 pomenopauzalnych chorych w wieku od 47 do 75 lat (mediana: 64,5), któ-
re zakwalifikowano do podawania anastrozolu. Wszystkie chore uprzednio otrzymywa∏y tamoksyfen jako leczenie uzupe∏nia-
jàce (n=31) lub paliatywne w chorobie zaawansowanej (n=13). Podstawowe parametry lipidowe krwi oraz wartoÊç wskaê-
nika masy cia∏a (waga w kilogramach podzielona przez wzrost w metrach do kwadratu) oceniono przed w∏àczeniem anastro-
zolu i po 12-32 tygodniach (mediana: 13, Êrednia: 16,2) podawania preparatu w dawce 1 mg dziennie doustnie.
W y n i k i.  W trakcie stosowania anastrozolu nie zaobserwowano statystycznie znamiennych zmian st´˝eƒ cholesterolu ca∏ko-
witego (p=0,50), cholesterolu – LDL (p=0,51), cholesterolu – HDL (p=0,69), trójglicerydów (p=0,95) oraz odsetka chorych
z poziomem cholesterolu ca∏kowitego powy˝ej normy (> 5,7 mmol/l, p=0,85). Nie wykazano równie˝ wp∏ywu leku na Êred-
nie wartoÊci wskaênika masy cia∏a (p=0,94).
W n i o s k i.  Krótkotrwa∏e podawanie anastrozolu nie wp∏ywa na podstawowy profil lipidowy i wartoÊci wskaênika masy cia-
∏a u chorych na raka piersi dotychczas leczonych tamoksyfenem. Badanie jest kontynuowane celem oceny wp∏ywu d∏ugotrwa-
∏ego stosowania na parametry lipidowe i lipoproteinowe.
Key words: anastrozole, breast cancer, cholesterol, triglycerides, body weight
S∏owa kluczowe: anastrozol, rak piersi, lipidy, cholesterol, trójglicerydy, masa cia∏a
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Women suffering from hypertension, acute and chronic
liver failure and biliary tract diseases, endocrinological disorders
or treated with drugs that alter the lipid profile were excluded
from the study. Basic lipid parameters of blood and body mass
index values (weight in kilos divided by squared height in me-
ters) were estimated before administering anastrozole and after
12-32 weeks (median: 13, average: 16.2) of therapy. After an
overnight fast, blood was obtained by venipuncture the follo-
wing morning between 07.00. and 09.00. hours. Serum total-
and HDL-cholesterol concentrations were analyzed by enzy-
matic methods using Abbot VP bichromatic analyzer [17, 18].
HDL-cholesterol was estimated after previous precipitation of
apoprotein B containing lipoproteins with dextrane sulfate
(0.1 mg/ml, MW 5 x 105; Pharmacia) and magnesium chloride
(0.05 x 10-3 mmol/l) [18]. LDL-cholesterol concentration valu-
es were calculated according to the Friedewald formula [19].
The cut off level of total cholesterol to determine hyperchole-
sterolemia was defined at 5.70 mmol/l (220 mg/dl).
Statistical calculations were performed using the paired
Student's t test, and chi-square test with Yate's continuity correc-
tion. p-values below 0.05 were considered to be significant.
Results
There was no statistically significant change over time in
basic lipid parameters, i.e. total- (p=0.50), LDL –
(p=0.51), HDL-cholesterol (p=0.69), triglycerides
(p=0.95) as well as the percentage of hypercholestero-
lemic cases (p=0.85). No effect of anastrozole therapy
on the body mass index values (p=0.94) was found. Ta-
ble II presents the results of the study.
Discussion
Anastrozole, together with letrozole and vorozole, consti-
tute a group of oral non-steroid third-generation aroma-
tase inhibitors [20]. Unlike aminoglutethimide, anastrozo-
le is marked by a better tolerance and greater selectivity
of aromatase inhibition [20]. Thus, administering doses
even 60 times higher than these clinically applied does
not upset the hydroxylation of sterols metabolised by en-
zymes of cytochrome P-450 and does not necessitate sup-
plementation with glycocorticoids [20]. Application of 1
mg of anastrozole on a daily basis leads to a significant de-
crease in estrogen concentration within three hours, whe-
reas with three day treatment estradiol concentration
falls beneath the level detectable by available tests [20,
21]. It remains in the range of 17% of the initial value
throughout the therapy [21]. Although anastrozole ap-
plied in short courses causes some inhibition of estrogen
synthesis, while, in turn, estrogenes are the main regula-
tors of lipid metabolism, no changes were observed in
basic lipid parameters in our pilot group of 44 patients
(duration of treatment – median: 13 weeks, average: 16.2,
range: 12-32). These results are consistent with our pre-
vious observations [22].
All the patients enrolled in the study had previously
received tamoxifen for 3 to 51 months (median: 15),
prior to anastrozole. The beneficial effect of the for-
mer drug on lipid metabolism has been well substantia-
ted [4, 6, 9]. Our observation to the effect that applying
Tab. I. Clinical characteristics of the study group
Age – years:
- average 61.6
- median 64.5
- range 47-75
Initial treatment:
- chemiotherapy 17
- radical mastectomy 27
Adjuvant treatment:
- chemiotherapy 11
- hormonotherapy 31
- no treatment 2
Estrogen receptor
- positive 27
- unknown 17
Menopause:
- natural 40
- surgical 2
- LHRH analogs* 2
Duration of anastrozole therapy – weeks:
- average 16.2
- median 13
- range 12-32
* – treatment was continued during anastrozole administration
Tab. II. Changes in total-, HDL-, LDL-cholesterol and triglycerides serum concentrations and body mass index in breast cancer patients during
anastrozole treatment
Investigated parameters Mean value before Mean values in the course p – statistic 
treatment ± SD of treatment ± SD significance
Total cholesterol [mmol/l] 5.44 ± 0.79 5.64 ± 0.71 p = 0.50
LDL cholesterol [mmol/l] 2.99 ± 0.90 3.22 ± 0.96 p = 0.51
HDL cholesterol [mmol/l] 1.38 ± 0.27 1.42 ± 0.30 p = 0.69
Triglycerides [mmol/l] 1.71 ± 0.94 1.69 ± 0.90 p = 0.95
Number and (percentage)
of hypercholesterolemic patients 18 (40.9%) 20 (45.5 %) p = 0.85
Body mass index [kg\m2] 26.79 ± 6.16 26.62 ± 6.08 p = 0.94
SD – standard deviation
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anastrozole does not reverse the effect(s) of prior ta-
moxifen on lipid metabolism is relevant in the sense
that aromatase inhibitors are currently investigated for
treatment of early breast cancer in adjuvant setting, and
in some studies non-steroidal aromatase inhibitors are
given sequentially to initial tamoxifen treatment. In
ARNO trial (Arimidex versus Nolvadex) by the German
Breast Cancer Group, after 2 years of tamoxifen pa-
tients are randomly assigned either to an anastrozole
group, or tamoxifen is continued for three years [16,
20]. The BIG/FEMTA trial (the Breast International
Group Femara and Tamoxifen Trial) has side arms of
a similar design, but employing letrozole [16, 20]. The
MA17 study by the National Cancer Institute of Canada
– Clinical Trial Group randomizes recurence-free pa-
tients following adjuvant treatment with tamoxifen for 5
years to either placebo or to another 5 year-treatment
with letrozole [16, 20].
In view of prospective use of aromatase inhibitors se-
quentially to initial adjuvant tamoxifen, evaluation of the
long-term effects of therapy with these drugs on lipid me-
tabolism seems particularly important. The subject has
not been thoroughly discussed in literature. To our know-
ledge, only one study evaluating the effects of new-ge-
neration aromatase inhibitors on the concentration of
several blood parameters crucial in defining the possible
risk of heart disease has been published [23]. In the study
of L. Costa et al. a group of 21 postmenopausal advanced
breast cancer patients was estimated for a potential influ-
ence of fadrozole, a non-steroidal aromatase inhibitor of
second generation, on lipid metabolism [23]. All the pa-
tients were previously on tamoxifen, but the treatment
was discontinued at least one month before the analysis.
In the course of treatment lasting 3 to 24 months (avera-
ge: 15.8) no statistically significant changes were obse-
rved in the concentrations of total cholesterol, triglyceri-
des, high-, low- and very low-density lipoproteins [23].
Similar observations were made during our former study
[24]. We evaluated 30 postmenopausal breast cancer pa-
tients treated with non-steroidal aromatase inhibitors
(anastrozole n=27, letrozole n=3) for at least 24 weeks
(range: 25-52, median: 32). All the patients were previo-
usly on tamoxifen as adjuvant treatment (n=21), or in
palliative setting (n=9). No changes were discovered in le-
vels of the basic lipid parameters of blood (total-, HDL-,
LDL- cholesterol and triglycerides), nor in the percenta-
ge of patients with elevated values of total cholesterol.
However, their body mass index increased significantly
(28.4±4.4 vs. 29.5±3.8 kg\m2, p=0.048). Such observa-
tions [23, 24], based on the analysis of relatively low num-
ber groups suggest, however, that long-term therapy with
non-steroid aromatase inhibitors does not have a detri-
mental effect on the lipid profile in patients with breast
cancer.
The question to be answered now is: why a drug,
which strongly suppresses estrogen synthesis and is ap-
plied after tamoxifen, which in turn positively affects lipid
metabolism as an ER agonist, is of no effect on basic lipid
parameters? The data from studies conducted in the
90's may offer a potential explanation. Lipid metabolism
regulation in tamoxifen patients has been demonstrated
to be dominated by other factors than the drug's estrogen-
-like activity in the liver [25, 26]. Tamoxifen and toremifen
(another antiestrogen coumpound in breast cancer treat-
ment) inhibit delta-8 isomerase, and thus block the co-
nversion of delta 8-cholesterol to lethosterol [25, 26]. It le-
ads to decrease in total- and LDL-cholesterol levels cau-
sed by the down-regulation of cholesterol synthesis [25,
26]. Such an inhibition, however, does not affect the levels
of HDL-cholesterol or triglycerides [26]. So far, non-ste-
roidal aromatase inhibitors have been proven to have no
effect on the activity of enzymes in metabolism of chole-
sterol or other lipids [23].
Conclusions
1. Short-term application of anastrozole does not affect
the basic lipid profile nor the body mass index in breast
cancer patients, previously on tamoxifen.
2. The study will be continued to evaluate possible ef-
fects of long term anastrozole application on lipid and
lipoprotein parameters.
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